reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
Sodium compounds have been known since ancient times; salt (sodium chloride) has been an important commodity in human activities. While potash has been used since ancient times, it was not understood for most of its history to be a fundamentally different substance from sodium mineral salts. Georg Ernst Stahl obtained experimental evidence which led him to suggest the fundamental difference of sodium and potassium salts in 1702, and Henri-Louis Duhamel du Monceau was able to prove this difference in 1736. The exact chemical composition of potassium and sodium compounds, and the status as chemical element of potassium and sodium, was not known then, and thus Antoine Lavoisier did not include either alkali in his list of chemical elements in 1789. Pure potassium was first isolated in 1807 in England by Humphry Davy, who derived it from caustic potash (KOH, potassium hydroxide) by the use of electrolysis of the molten salt with the newly invented voltaic pile. Previous attempts at electrolysis of the aqueous salt were unsuccessful due to potassium's extreme reactivity. Potassium was the first metal that was isolated by electrolysis. Later that same year, Davy reported extraction of sodium from the similar substance caustic soda (NaOH, lye) by a similar technique, demonstrating the elements, and thus the salts, to be different.
TATP decomposes explosively; examination of the explosive decomposition of TATP at the very edge of detonation front predicts "formation of acetone and ozone as the main decomposition products and not the intuitively expected oxidation products." Very little heat is created by the explosive decomposition of TATP at the very edge of the detonation front; the foregoing computational analysis suggests that TATP decomposition is an entropic explosion. However, this hypothesis has been challenged as not conforming to actual measurements. The claim of entropic explosion has been tied to the events just behind the detonation front. The authors of the 2004 Dubnikova et al. study confirm that a final redox reaction (combustion) of ozone, oxygen and reactive species into water, various oxides and hydrocarbons takes place within about 180 ps after the initial reaction—within about a micron of the detonation wave. Detonating crystals of TATP ultimately reach temperature of 2,300 K (2,030 °C; 3,680 °F) and pressure of 80 kbar. The final energy of detonation is about 2800 kJ/kg (measured in helium), enough to briefly raise the temperature of gaseous products to 2,000 °C (3,630 °F). Volume of gases at STP is 855 L/kg for TATP and 713 L/kg for DADP (measured in helium). The tetrameric form of acetone peroxide, prepared under neutral conditions using a tin catalyst in the presence of a chelator or general inhibitor of radical chemistry, is reported to be more chemically stable, although still a very dangerous primary explosive. Its synthesis has been disputed.
The Spanish conquistador Hernán Cortés's capture of Tenochtitlan in 1521 initiated the widespread cultural and biological interchange called the Columbian exchange. The tomato was cultivated in Europe only a few years after that event, by the 1540s, and grew easily in the Mediterranean climates. The earliest mention of the tomato in European literature appeared in Pietro Andrea Mattioli's 1544 herbal. He suggested that a new type of eggplant had been brought to Italy. He stated that it was blood-red or golden in color when mature and could be divided into segments and eaten like an eggplant, that is, cooked and seasoned with salt, black pepper, and oil. Ten years later, Mattioli named the fruits in print as pomi d'oro, or "golden apples". It was probably eaten shortly after it was introduced, and tomatoes were used as food by the early 17th century in Spain, as documented in the 1618 play La octava maravilla by Lope de Vega with "lovelier than ... a tomato in season". After the Spanish colonization of the Americas, the Spanish distributed the tomato throughout their colonies in the Caribbean. After they introduced it to the Philippines, it spread to Southeast Asia and then across Asia.
== Future == Two prequels, Cold War 1994 and Cold War 1995, were announced at the Hong Kong Cinema panel for 2025 Cannes Film Festival from Edko. Both films were shot simultaneously back to back in 2024 with Longman Leung returning as director and writer, in addition to new cast members including Daniel Wu, Terrance Lau and Wu Kang-ren. The story follows a younger MB Lee during the years leading up to the Handover of Hong Kong as he navigates the world between the triads, police force, and the colonial and elite circle. A first poster and teaser trailer for Cold War 1994 was released on June 17th, 2025, and officially released on May 1st, 2026, while Cold War 1995 is slated to release either in late 2026 or 2027.
== Structure == MCH is a cyclic 19-amino acid neuropeptide, as it is a polypeptide chain that is able to act as a neurotransmitter. MCH neurons are mainly concentrated in the lateral hypothalamic area, zona incerta, and the incerto-hypothalamic area, but they are also located, in much smaller amounts, in the paramedian pontine reticular formation (PPRF), medial preoptic area, laterodorsal tegmental nucleus, and the olfactory tubercle. MCH is activated by binding to two G-coupled protein receptors (GCPRs), MCHR1 and MCHR2. MCHR2 has only been identified in certain species such as humans, dogs, ferrets, and rhesus monkeys, while other mammals such as rodents and rabbits do not have the receptor. MCH is cleaved from prepro-MCH (ppMCH), a 165 amino acid polypeptide which also contains the neuropeptides GE and EI.
Sources: en.wikipedia.org
=== FDA warning letters === During the 21st century, the FDA issued multiple warning letters to American manufacturers of yohimbe supplements for making false health claims and interstate marketing of such products as misbranded, unapproved drugs.
=== Not radioactive === Irradiated food does not become radioactive; only particle energies that are incapable of causing significant induced radioactivity are used for food irradiation. In the United States this limit is 4 mega electron volts (MEV) for electron beams and x-ray sources—cobalt-60 or caesium-137 sources are never energetic enough to induce radioactivity. Particles below this energy can never be energetic enough to modify the nucleus of the targeted atom in the food, regardless of how many particles hit the target material, and so radioactivity can not be induced.
=== Plastics === Calcium carbonate is commonly used in the plastic industry as a filler. When it is incorporated in a plastic material, it can improve the hardness, stiffness, dimensional stability and processability of the material.
== Certification == In the US, three organizations are responsible for the certification of trained internists (i.e., doctors who have completed an accredited residency training program) in terms of their knowledge, skills, and attitudes that are essential for patient care: the American Board of Internal Medicine, the American Osteopathic Board of Internal Medicine and the Board of Certification in Internal Medicine. In the UK, the General Medical Council oversees licensing and certification of internal medicine physicians. The Royal Australasian College of Physicians confers fellowship to internists (and sub-specialists) in Australia. The Medical Council of Canada oversees licensing of internists in Canada.
Sources: en.wikipedia.org
== Medical use == A 2018 Cochrane review found that fluphenazine was an imperfect treatment and other inexpensive drugs less associated with side effects may be an equally effective choice for people with schizophrenia. Another 2018 Cochrane review found that there was limited evidence that newer atypical antipsychotics were more tolerable than fluphenazine. Intramuscular depot injection forms are available as both the decanoate and enanthate esters.
Enobosarm reached phase 2 clinical trials for this indication, but development was discontinued due to lack of effectiveness in a phase 2 study. Subsequently, enobosarm was repurposed again for the treatment of androgen receptor-positive (AR+) estrogen receptor-positive (ER+) breast cancer. As of November 2023, it is in phase 3 clinical trials for the treatment of this type of breast cancer. Increases in lean body mass and muscle strength as a secondary benefit with enobosarm are also being evaluated in these women. These trials are notably employing several-fold higher doses of enobosarm than were assessed in the muscle wasting phase 3 trials (9 mg/day versus 3 mg/day, respectively). In January 2024, it was announced that enobosarm was being developed for prevention of muscle wasting and augmentation of fat loss in combination with glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide for weight loss. A phase 2b clinical trial for this indication with 3 to 6 mg/day enobosarm in sarcopenic obese or overweight elderly individuals is being prepared. According to GTx, the original developer of enobosarm, a total of 25 clinical studies have been carried out on more than 1,700 people involving doses from 1 to 100 mg as of 2020. However, enobosarm has not yet completed clinical development or been approved for any use.
Types include astrocytes, oligodendrocytes, microglia, and Schwann cells. Glia limitans A thin layer of astrocytic endfeet beneath the pia mater that forms part of the barrier separating the brain parenchyma from the cerebrospinal fluid. Glial scar A dense accumulation of glial cells, particularly astrocytes, that forms after central nervous system injury. It helps contain damage but can also inhibit axonal regeneration. Glioblastoma A highly aggressive and malignant brain tumor arising from glial cells. It is the most common primary brain cancer in adults and often has a poor prognosis. Glucocorticoid A class of steroid hormones released by the adrenal cortex in response to stress. They influence metabolism and have significant effects on memory and the hippocampus. Glutamate The main excitatory neurotransmitter in the brain. It is essential for learning, memory, and synaptic plasticity, but excessive levels can cause excitotoxicity. Glutamatergic Describes neurons or synapses that use glutamate as a neurotransmitter. These are the majority of excitatory synapses in the brain. Glycine An inhibitory neurotransmitter found primarily in the spinal cord and brainstem. It acts via glycine receptors and contributes to motor control and reflexes. Golgi cell A type of inhibitory interneuron in the cerebellum that regulates input from mossy fibers to granule cells via GABA release. Golgi stain A silver staining method that randomly labels a small subset of neurons in their entirety, allowing detailed study of neuronal morphology.
When Lee approved the proposal after such widespread criticism, the opposition said that he had overruled consensus. The issue of casinos in Singapore was brought up by parliamentary members such as Denise Phua suggesting that the place of gambling in Singapore be reviewed during a parliament session discussing Remote Gambling Bill.
== Changes during ontogeny == In the rat blood plasma, the GPx-3 activity is low during the first two weeks after birth and rapidly increasing during transition from milk nutrition to solid food. Aging is accompanied by decrease in GPx-3 activity: in the blood plasma of rats it occurs around 23-26 months of age.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
Dry powder is normally held at -20 °C or lower, away from light and moisture. Sealed vials can also be kept at 2-8 °C for shorter intervals. Warming to room temperature before opening prevents condensation.